Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chugai Applies For Expiration Date Extension On Stockpiled Tamiflu

This article was originally published in PharmAsia News

Executive Summary

The Japanese importer of the flu drug Tamiflu, Chugai Pharma, has applied to the Ministry of Health, Labor and Welfare to extend the expiration date of the product, which is stockpiled by Japanese national and local governments, from the current five years to seven years. To prepare for a possible flu pandemic, the government and local authorities have invested ¥54.4 billion to stockpile Tamiflu. Under the current expiration date, some of that stockpile will expire in two years and have to be disposed of. (Click here for more-Japanese language)

You may also be interested in...



Japanese Chugai Revises First Quarter Profit Outlook

TOKYO - Chugai Pharmaceutical said April 22 its net income in the first quarter dropped by roughly 50 percent compared to the same period last year due to weak sales of its influenza vaccine Tamiflu (oseltamivir). However, the Tokyo-based company revised and lifted its profit outlook until the end of the year in part due to lower than expected drug repricing efforts by the government

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

UsernamePublicRestriction

Register

LL1133229

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel